MedPath

Clinical Trial News

Roche's CPHPC Drug Shows Promise in Breaking Down Alzheimer's Amyloid Clumps

  • Swiss, British and Japanese researchers have found that Roche's non-toxic drug CPHPC can erode amyloid protein clumps that build up in Alzheimer's patients' brains.
  • The drug works by targeting serum amyloid P component (SAP), which binds amyloid clumps together and makes them resistant to natural breakdown.
  • Clinical trials are set to begin for this novel therapeutic approach that could potentially slow the onset of dementia in Alzheimer's sufferers.
  • Professor Mark Pepys, who has worked on this concept for 25 years, expressed significant excitement about the drug's ability to perform exactly as intended.

Intensive Chemo Shows Promise in Relapsed Ovarian Cancer

  • A new intensive chemotherapy regimen demonstrates high effectiveness in treating women with relapsed ovarian cancer after initial chemotherapy failure.
  • The treatment, combining cisplatin and etoposide, achieved an 80% tumor shrinkage rate, with 43% of patients showing complete remission.
  • The intensive regimen, involving weekly cisplatin administration, proved more effective than standard therapies, offering new hope for patients with limited options.
  • Researchers noted the treatment was well-tolerated, with manageable side effects, and the drugs are readily available for immediate patient benefit.

ASCO 2024: Lenvatinib plus Pembrolizumab Shows Superiority Over Sunitinib in Advanced Renal Cell Carcinoma

At the 2024 ASCO Annual Meeting, Dr. Viktor Grünwald presented findings from the CLEAR trial, highlighting the efficacy of lenvatinib plus pembrolizumab over sunitinib in treating advanced clear cell renal cell carcinoma. The combination therapy demonstrated significant improvements in overall survival, prolonged time to tumor progression across various organs, and a lower median tumor burden at disease progression.

Regional Chemotherapy for Liver Metastases of Colorectal Cancer Shows Varied Perfusion Patterns

A study involving 82 patients with liver metastases from colorectal cancer treated with continuous chemotherapy via hepatic artery infusion pumps revealed varied liver perfusion patterns. While 70% of patients showed homogeneous liver perfusion, 24% had distinct inhomogeneities, and 6% exhibited selective perfusion of one hepatic lobe, impacting the response to therapy.

D3Bio's Novel KRAS-G12C Inhibitor Shows Promising Results in Phase 1 Cancer Trial

OncologyPrecision MedicineTargeted Therapy
  • A multinational study led by Chinese University researchers found that D3S-001, a mainland-developed KRAS-G12C inhibitor, demonstrated significant efficacy with over 70% of patients experiencing tumor shrinkage or disappearance.
  • The novel compound from D3Bio inhibits KRAS-G12C mutations at a faster rate and potentially longer duration than existing treatments, according to Dr. Herbert Loong from CUHK's Department of Clinical Oncology.
  • Researchers are planning phase 3 trials with the goal of positioning D3S-001 as a first-line treatment option for patients with KRAS-G12C-driven cancers of the lung, pancreas, and colon.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.